Wolfe Laboratories Addresses Rapid Growth with Executive Appointment

Woburn, Mass. — June 14, 2016 — Wolfe Laboratories, Inc. today announced that Frank Tagliaferri, Ph.D., has been appointed Vice President, Pharmaceutical Development, effective immediately. Dr. Tagliaferri will lead technical operations for Wolfe’s rapidly growing client base, bringing a wealth of experience in analytical methodologies, formulation and process development, scale-up, and regulatory functions across highly diverse therapeutic modalities, including small molecules, peptides, proteins, and nucleic acid therapeutics. Dr. Tagliaferri will serve as a member of Wolfe’s executive leadership team and will report to Janet Wolfe, the company's President and Chief Executive Officer.

“Frank’s proven track record of success in developing and commercializing a broad range of novel therapeutics and dosage forms is essential to Wolfe Laboratories as we grow to meet increased client demand for a strong pharmaceutical development CRO partner,” said Dr. Janet Wolfe. “I am thrilled to have the opportunity to work with Frank; he brings outstanding strategic leadership and technical acumen that will greatly benefit our clients’ programs and overall company growth.”

Most recently, Dr. Tagliaferri co-founded and served as Vice President of R&D at 4P Therapeutics with a focus on the design, characterization, and commercial development of novel delivery systems and drug/device combination products for biologics and other complex molecules. Prior to joining 4P Therapeutics in 2012, Dr. Tagliaferri served as Vice President of R&D for Altea Therapeutics where he contributed to the development of the PassPort® System for the transdermal delivery of small molecules and biologics. Dr. Tagliaferri began his career at GeneMedicine (later Valentis, Inc.) where, as Director of Drug Delivery, his focus was on the development and characterization of delivery systems for both DNA and proteins. He later served the same role at Tapestry Pharmaceuticals working on small molecule anti-cancer agents and novel RNA-based therapeutics.

“Wolfe Laboratories’ integrated pharmaceutical development services are making a meaningful difference for advancing pipelines at its clients’ companies,” said Dr. Frank Tagliaferri. “I’m excited to join an outstanding team and help Wolfe Laboratories leverage its sophisticated development expertise.”

Dr. Tagliaferri earned his Ph.D. in Chemistry from the University of Virginia and a B.A. in Chemistry from Franklin and Marshall College. He was a postdoctoral fellow at the University of Tennessee.

About Wolfe Laboratories

Wolfe Laboratories, Inc. is a premier contract research organization that provides integrated drug development solutions to the biopharmaceutical industry. Wolfe Laboratories is an essential element of the drug development ecosystem, recognized by global and virtual biopharmaceutical companies as a science-driven organization whose mission is to provide outstanding discovery and development services tailored to its clients’ needs for rational formulation development. Wolfe Laboratories integrates the critical path components of early development to ensure that programs advance while meeting rigorous scientific demands with flexibility to address dynamic challenges and aggressive timelines. Wolfe Laboratories’ vision is to improve human health, and we continue to strive towards that goal by embracing our core values of integrity, excellence and teamwork. The company has a high percentage of repeat clients, which is a testament to its long-term commitment of continual investment in its capabilities to meet biopharma's growing demand for high quality, integrated early development services. Founded in 1999, the company is located in Woburn, Massachusetts.

For more information, please visit www.wolfelabs.com.


Media Contact:

Karen Sharma
MacDougall Biomedical Communications